Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

NCT05896930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Tuberculosis

Interventions

DRUG: Meropenem 6g IV over 6 hours
DRUG: Ertapenem 1g IM
DRUG: Meropenem 3g IV
DRUG: Ertapenem 1g IV
DRUG: Amoxicillin/CA twice daily
DRUG: Rifampicin 35 mg/kg
DRUG: Meropenem 6g IV over 60 minutes
DRUG: Rifafour e-275
DRUG: Meropenem 4g IV
DRUG: Amoxicillin/CA once daily

Sponsor

TASK Applied Science